Latest Administration News

Aura Energy announces a strategic collaboration with Neu Horizon Uranium Ltd to advance uranium mining in Sweden, aligning with the Swedish government’s plans to lift its uranium mining ban and bolster nuclear energy production.

EVE Health Group has initiated stability testing for its novel oral treatments targeting erectile dysfunction and dysmenorrhea, marking a crucial step toward regulatory approval in Australia. The company also finalizes its acquisition of Nextract, the developer behind these innovative formulations.

Sultan Resources Ltd has announced a pro rata non-renounceable rights issue to raise approximately $1.16 million, aiming to fund exploration activities and strengthen working capital. The offer opens on June 11 and closes on June 20, 2025.

ANZ Group Holdings Limited has updated its interim dividend details, confirming an 83-cent payout per share, partially franked at 70%, payable on July 1, 2025. The bank also outlined its Dividend Reinvestment and Bonus Security Plans with shares priced at AUD 28.89.

Fintech Chain Limited reported a 24% revenue increase to RMB55.9 million for FY2025 driven by new SaaS products, yet it remains in the red with a net loss of RMB4.8 million. The company has also applied for delisting from the ASX.

Helios Energy Limited has come under ASX compliance scrutiny after late lodgement of director interest notices, raising questions about its disclosure practices and governance.

Papyrus Australia reported a $52,000 operating cash outflow for April 2025 but bolstered its liquidity with $239,000 in financing inflows, extending its funding runway to over a year.

Amplia Therapeutics reports strong progress in its pancreatic cancer drug development, completing the ACCENT trial recruitment ahead of schedule and initiating a new US trial, while managing a $6.57 million loss for FY25.

Mount Hope Mining Limited has announced a non-renounceable pro-rata Loyalty Option Offer to raise approximately $103,125, aiming to bolster exploration funding and reward shareholder loyalty.

Little Green Pharma Ltd has reported a robust turnaround for FY2025, posting a $3.3 million profit after tax on revenues up 43%, driven by strong growth in Australia and Europe and strategic acquisitions.

Pacific Edge Limited reported a resilient FY25 performance despite losing Medicare coverage for its Cxbladder tests in the US, announcing a $20 million equity raise to support commercialization and growth.

8I Holdings Limited reported a net loss of S$1.09 million for FY2025, impacted by a sharp decline in investment gains due to global market volatility and new U.S. tariffs. The Group remains focused on a conservative, value-driven investment strategy despite challenging conditions.